Breast cancer is a silent disease that kills many women across the world each year. Now, a research team out of University of North Texas (UNT) believes their latest research throws a wrench into the spread of this disease.
The team of scientists have found a protein that is linked to the growth of tumors. What’s more, they have also discovered a way to treat it. The discoveries are so groundbreaking that they are all stunned by it. No one was expecting a surprise of this magnitude.
The protein in question is called the NAF1 protein, and was discovered by a team of researchers headed up by Dr. Ron Mittler PhD, a professor at UNT’s Department of Biological Scienes and the BioDiscovery Institute.
According to Dr. Mittler, when our bodies over express protein, we get tumors that are very huge. These tumors grow a lot faster than normal tumors. When we attack the tumors, they are abolished completely. This is true especially for a very lethal and aggressive form of breast cancer tumors called triple negative.
Right now, there is no known effective way to treat triple negative breast cancer, so the hope is that this new research will help increase chances of survival for this type of cancer patients.
Even better – a drug that used to treat Type 2 diabetes that is already FDA approved has been shown to destroy the NAF1 protein.
Co-researcher Rachel Nechushtai, a professor at The Hebrew University in Jerusalem and adjunct professor at UNT, has been emphasizing how monumental this discovery is. In fact, the researchers plan to begin clinical trials based on their findings in Israel this November.
According to Dr. Mittler, now that they have narrowed down what it is they are targeting in the protein, they will be able to tailor this specific drug to increase its efficiency and lower its side effects.
Dr. Mittler’s efforts against breast cancer has a personal component, as his own mother passed away from triple negative breast cancer 15 years ago. It is his hope that these findings give a new lease on life to many breast cancer patients.